GlassScriptPhysician profile
Brian L Minkus
NPI 1235165507
$4,015.00
in general payments reported to CMS, 2019-2025
30 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $868 · 2021: $886 · 2022: $539 · 2023: $281 · 2024: $374 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $527.57 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $519.01 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $350.26 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $287.05 | 2022-2025 | |
| Glaxosmithkline, LLC. | $238.06 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $210.66 | 2019-2021 | |
| Allergan, INC. | $207.87 | 2019-2020 | |
| Amarin Pharma, INC. | $185.38 | 2020-2021 | |
| Abbvie INC. | $173.88 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.75 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $130.70 | 2021-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $105.46 | 2023-2025 | Jardiance, Mounjaro |
| Novartis Pharmaceuticals Corporation | $103.17 | 2019-2024 | |
| Vanda Pharmaceuticals INC. | $100.77 | 2020-2021 | |
| Astellas Pharma US INC | $90.88 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $87.00 | 2021 | |
| Radius Health, INC. | $86.87 | 2019-2024 | Tymlos |
| Almatica Pharma LLC | $75.06 | 2021-2025 | Loreev Xr |
| Philips North America LLC | $68.67 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Eisai INC. | $63.44 | 2021 | |
| Exact Sciences Corporation | $47.01 | 2023-2024 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $33.34 | 2021 | |
| Gilead Sciences, INC. | $31.02 | 2022 | |
| Antares Pharma, INC. | $30.89 | 2019 | |
| Azurity Pharmaceuticals, INC. | $27.79 | 2025 | Edarbi |
| Phathom Pharmaceuticals, INC. | $25.52 | 2025 | Voquezna |
| Hologic Sales and Service, LLC | $22.23 | 2025 | Aptima, Thinprep 2000 Processor |
| Circassia INC. | $15.56 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.23 | 2019 | |
| Mylan Pharmaceuticals INC. | $14.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Minkus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.